Yanju Cheng

Title: Yanju Cheng: Innovator in Pharmaceutical Antibody Formulations

Introduction

Yanju Cheng is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical compositions, particularly focusing on humanized monoclonal antibodies. His innovative work has the potential to impact the treatment of various diseases.

Latest Patents

Yanju Cheng holds a patent for a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody. This invention relates to antibody formulations and comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer, and 0.01-0.8 mg/ml of a surfactant. The pH of the formulation is maintained at about 4.5-6.8. This formulation is designed to prevent the increase of antibody aggregates while ensuring the long-term maintenance of the biological binding activity of the antibody.

Career Highlights

Throughout his career, Yanju Cheng has worked with prominent companies in the pharmaceutical industry. Notable among these are Nanjing Shunxin Pharmaceutical Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Yanju Cheng has collaborated with several professionals in his field, including Jianwen Li and Yingchun Li. These collaborations have likely enhanced his research and development efforts in antibody formulations.

Conclusion

Yanju Cheng is a distinguished inventor whose work in pharmaceutical compositions, particularly in humanized monoclonal antibodies, showcases his innovative spirit and dedication to advancing medical science. His contributions are poised to make a significant impact in the field of therapeutics.